References
- Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
- Kresovich JK, Xu Z, O’Brien KM, et al. Methylation-based biological age and breast cancer risk. JNCI. 2019;111(10):1051–1058.
- Johnson KC, Koestler D, Cheng C et al. Age-related DNA methylation in normal breast tissue and its relationship with invasive breast tumor methylation. Epigenetics. 2014;9(2):268–275.
- Klutstein M, Nejman D, Greenfield R, et al. DNA methylation in cancer and aging. Cancer Res. 2016;76(12):3446–3450.
- Johnson KC, Houseman EA, King JE, et al. Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age. Breast Cancer Res Treat. 2017;19(1):81.
- Song M-A, Brasky TM, Weng DY, et al. Landscape of genome-wide age-related DNA methylation in breast tissue. Oncotarget. 2017;8(70):114648.
- Dumitrescu R, Marian C, Krishnan SS, et al. Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women. J Cell Mol Med. 2010;14(6b):1468–1475.
- Song M-A, Brasky TM, Marian C, et al. Racial differences in genome-wide methylation profiling and gene expression in breast tissues from healthy women. Epigenetics. 2015;10(12):1177–1187.
- Sung H, Rosenberg PS, Chen W-Q, et al. Female breast cancer incidence among Asian and Western populations: more similar than expected. JNCI. 2015;107(7):djv107.
- Li M, Tse LA, Chan W-C, et al. Nighttime eating and breast cancer among Chinese women in Hong Kong. Breast Cancer Res Treat. 2017;19(1):31.
- Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61.
- Fortin J-P, Labbe A, Lemire M, et al. Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol. 2014;15(11):503.
- Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12(1):323.
- Paquet ER, Hallett MT. Absolute assignment of breast cancer intrinsic molecular subtype. J Natl Cancer Inst. 2014;107(1):dju357.
- Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612.
- Madden SF, Clarke C, Gaule P, et al. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res Treat. 2013;15(4):R52.
- Deevi RK, Cox OT, O’Connor R. Essential function for PDLIM2 in cell polarization in three-dimensional cultures by feedback regulation of the β1-integrin–RhoA signaling axis. Neoplasia. 2014;16(5):422–431.
- Lee K, Kitagawa M, Liao P, et al. A Ras-LSD1 axis activates PI3K signaling through PIK3IP1 suppression. Oncogenesis. 2020;9(1).
- Kikuchi M, Yamashita K, Waraya M, et al.. Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer. Oncotarget. 2016;7(2):1741.
- Chimge N-O, Ahmed-Alnassar S, Frenkel B. Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive breast cancer. Cell Cycle. 2017;16(4):312–318.
- Rypens C, Marsan M, Van Berckelaer C, et al. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. Breast Cancer Res Treat. 2020;180(2):385–395.
- Singha PK, Pandeswara S, Geng H, et al. Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer. Genes Cancer. 2019;10(5–6):134.
- Lee SJ, Chae YS, Kim JG, et al. AQP5 expression predicts survival in patients with early breast cancer. Ann Surg Oncol. 2014;21(2):375–383.
- Lee SJ, Kang BW, Kim JG, et al. AQP5 variants affect tumoral expression of AQP5 and survival in patients with early breast cancer. Oncology. 2017;92(3):153–160.
- Morris MR, Ricketts CJ, Gentle D, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 2011;30(12):1390. DOI:10.1038/onc.2010.525.
- Yang X, Zhang Z, Qiu M, et al. Glypican-5 is a novel metastasis suppressor gene in non-small cell lung cancer. Cancer Lett. 2013;341(2):265–273.
- Jjingo D, Conley AB, Yi SV, et al. On the presence and role of human gene-body DNA methylation. Oncotarget. 2012;3(4):462.
- Brenet F, Moh M, Funk P, et al. DNA methylation of the first exon is tightly linked to transcriptional silencing. PloS One. 2011 Jan
- Blagitko-Dorfs N, Schlosser P, Greve G, et al. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. Leukemia. 2019;33(4):945–956.
- Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44(11):1236.
- Legendre C, Gooden GC, Johnson K, et al. Whole-genome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancer. Clin Epigenetics. 2015;7(1):100.
- Pyronnet S, Bousquet C, Najib S, et al. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286(1–2):230–237.
- Jin Z, Mori Y, Hamilton JP, et al. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer. 2008;112(1):43–49.
- Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 2006;131(3):797–808.
- Jackson K, Soutto M, Peng D, et al. Epigenetic silencing of somatostatin in gastric cancer. Dig Dis Sci. 2011;56(1):125–130.
- Hannum G, Guinney J, Zhao L, et al.. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49(2):359–367.
- Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):3156.
- Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573.
- Castle JR, Lin N, Liu J, et al. Estimating breast tissue-specific DNA methylation age using next-generation sequencing data. Clin Epigenetics. 2020;12(1):1–14.
- Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371.
- White AJ, Kresovich JK, Xu Z, et al. Shift work, DNA methylation and epigenetic age. Int J Epidemiol. 2019;48(5):1536–1544.
- Hofstatter EW, Horvath S, Dalela D, et al. Increased epigenetic age in normal breast tissue from luminal breast cancer patients. Clin Epigenetics. 2018;10(1):112.
- Lei Y, Huang Y-H, Goodell MA. DNA methylation and de-methylation using hybrid site-targeting proteins. Genome Biol. 2018;19(1):187.
- Liu XS, Wu H, Krzisch M, et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell. 2018;172(5):979–992.
- Yan PS, Venkataramu C, Ibrahim A, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res. 2006;12(22):6626–6636.